Physician profile
Britton K Bishop
NPI 1386617314
$6,428.73
in general payments reported to CMS, 2019-2025
30 companies · $47.00 in 2025
The $47.00 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $696 · 2020: $1,370 · 2021: $1,612 · 2022: $1,180 · 2023: $821 · 2024: $703 · 2025: $47.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,571.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,570.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,203.79 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $808.53 | 2019-2024 | |
| Lilly USA, LLC | $745.45 | 2019-2024 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $450.42 | 2019-2024 | Farxiga, Airsupra |
| Amgen INC. | $419.51 | 2019-2023 | Evenity, Prolia |
| Abbvie INC. | $338.42 | 2021-2024 | Qulipta, Vraylar |
| Sanofi-Aventis U.S. LLC | $329.65 | 2019-2023 | |
| Glaxosmithkline, LLC. | $327.03 | 2020-2024 | Trelegy Ellipta |
| Allergan, INC. | $197.07 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $176.51 | 2020-2024 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $175.90 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $171.66 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $137.84 | 2021-2023 | Spravato |
| Eisai INC. | $125.85 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $98.76 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $88.25 | 2022 | |
| Dexcom, INC. | $77.28 | 2021-2024 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $72.45 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $69.80 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $60.75 | 2020-2022 | |
| Astellas Pharma US INC | $60.14 | 2020-2023 | Veozah |
| Inspire Medical Systems, INC. | $47.00 | 2025 | Inspire |
| Amarin Pharma, INC. | $44.43 | 2020-2021 | |
| Abbott Laboratories | $42.01 | 2019-2022 | |
| Shield Therapeutics INC | $38.05 | 2023-2024 | Accrufer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.27 | 2022-2024 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $30.22 | 2021 | |
| Xeris Pharmaceuticals, INC. | $23.57 | 2021 | |
| Genentech USA, INC. | $18.05 | 2019 | |
| Mannkind Corporation | $16.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Britton Bishop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.